scholarly article | Q13442814 |
P50 | author | José Pedro Gil | Q50907208 |
Maja Malmberg | Q53583779 | ||
Pedro E. Ferreira | Q54802189 | ||
Anders Björkman | Q80329586 | ||
Andreas Mårtensson | Q91539704 | ||
Zul Premji | Q114316221 | ||
Billy Ngasala | Q114316222 | ||
Anja M Carlsson | Q117264098 | ||
P2093 | author name string | Yngve Bergqvist | |
Max G Petzold | |||
Daniel Blessborn | |||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Tanzania | Q924 |
malaria | Q12156 | ||
Plasmodium falciparum malaria | Q18554672 | ||
Plasmodium falciparum | Q311383 | ||
lumefantrine | Q904464 | ||
P304 | page(s) | 873-882 | |
P577 | publication date | 2011-04-01 | |
P1433 | published in | Clinical Infectious Diseases | Q5133764 |
P1476 | title | Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial | |
P478 | volume | 52 |
Q37211878 | Adding a single low-dose of primaquine (0.25 mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial |
Q55449589 | Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. |
Q26783646 | Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data |
Q34267667 | Artemether-lumefantrine: an option for malaria |
Q34137766 | Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children |
Q43924014 | Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling |
Q37023164 | Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease. |
Q38865815 | Comparable lumefantrine oral bioavailability when co-administered with oil-fortified maize porridge or milk in healthy volunteers |
Q36776183 | Cost and Predictors of Care-Seeking Behaviors Among Caregivers of Febrile Children-Uganda, 2009. |
Q41827965 | Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar |
Q53686432 | Drug use in the management of uncomplicated malaria in public health facilities in the Democratic Republic of the Congo. |
Q34728230 | Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study |
Q43927844 | Effectiveness of artesunate-amodiaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial |
Q34922694 | Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola |
Q35833995 | Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania |
Q92463531 | How delayed and non-adherent treatment contribute to onward transmission of malaria: a modelling study |
Q36412071 | MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy |
Q28546804 | Measuring Patient Adherence to Malaria Treatment: A Comparison of Results from Self-Report and a Customised Electronic Monitoring Device |
Q26820807 | Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania |
Q38852053 | Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria |
Q37217604 | Open-label trial on efficacy of artemether/lumefantrine against the uncomplicated Plasmodium falciparum malaria in Metema district, Northwestern Ethiopia |
Q28075079 | Plasmodium falciparum drug resistance in Angola |
Q36584636 | Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms |
Q37279764 | Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria |
Q36108352 | Prevalence of K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated from adult symptomatic patients in northern Uganda |
Q64106192 | Prevalence of and Risk Factors Associated with Polymerase Chain Reaction-Determined Positivity on Day 3 after Initiation of Artemether-Lumefantrine Treatment for Uncomplicated Malaria in Bagamoyo District, Tanzania |
Q52615236 | Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. |
Q36080127 | Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact |
Q90135493 | Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo |
Q37038288 | Selection of pfdhfr/pfdhps alleles and declining artesunate/sulphadoxine-pyrimethamine efficacy against Plasmodium falciparum eight years after deployment in eastern Sudan |
Q54235937 | Semi-quantitative measurement of the antimalarial lumefantrine from untreated dried blood spots using LC-MS/MS. |
Q36526649 | Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study |
Q35834482 | Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges |
Q40075427 | Sustained High Cure Rate of Artemether-Lumefantrine against Uncomplicated Plasmodium falciparum Malaria after 8 Years of Its Wide-Scale Use in Bagamoyo District, Tanzania |
Q37066203 | Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania |
Q38529669 | The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine |
Q34253706 | Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania |
Q33605847 | Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia |
Q36489791 | Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin |
Q39206934 | pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies |
Search more.